MS4A6A antisense oligomer

MS4A6A antisense oligomers represent an emerging class of RNA-targeted therapeutics designed to treat Alzheimer's disease by modulating microglial function. MS4A6A is a member of the membrane-spanning 4-domain family and has been identified through genome-wide association studies (GWAS) as a significant genetic risk factor for Alzheimer's. It acts as a key regulator of TREM2 (Triggering Receptor Expressed on Myeloid cells 2) by influencing the proteolytic shedding of its extracellular domain, thereby controlling levels of soluble TREM2 (sTREM2) in the brain. These antisense oligonucleotides (ASOs) are engineered to reduce the expression of MS4A6A, which in turn is hypothesized to increase sTREM2 levels or enhance TREM2-mediated microglial clearance of amyloid-beta and other neurotoxic aggregates. Primarily developed through collaborations between academic institutions like Washington University in St. Louis and industry leaders such as Ionis Pharmaceuticals, these ASOs are currently in the preclinical stages of development, targeting the neuroinflammatory pathways central to neurodegeneration.

Other names

MS4A6A antisense oligonucleotideMS-4A6A antisense oligonucleotideMS 4A6A antisense oligonucleotideMS4A6A ASOMS-4A6A ASOMS 4A6A ASOMS4A6A antisense oligomerMS-4A6A antisense oligomerMS 4A6A antisense oligomer